Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

4.570 +0.150 (+3.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: 
Via Benzinga
North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026
Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept... 
Via FinancialNewsMedia
Compass Pathways (NASDAQ: CMPS) Announces Promising Data from Psilocybin Therapy Trial
Via Investor Brand Network
Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: 
Via Benzinga
Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same... 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Atai Life Sciences (NASDAQ: ATAI) Increases Stake in Psychedelic Start-Up Compass Pathways
Via Investor Brand Network
Cannabis Movers & Shakers: Coda Signature, Greater Cannabis Co., BioHarvest Sciences, Compass Pathways
Coda Signature Taps Teddy C. Scott As Board Member Producer of cannabis-infused edibles and wellness products Coda Signature 
Via Benzinga
Topics Cannabis
Exposures Cannabis
New York City Conference 'Horizons: Perspectives on Psychedelics' A Who's Who Of Notable Speakers
In a welcomed throwback to the days before psychedelic use and research was considered a forbidden topic, the conference “ 
Via Benzinga
Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November
A look at which critical stage drug stock category performed best in November and which constituents contributed to that performance. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher... 
Via Benzinga
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways
Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ:ATAI), a ... 
Via Benzinga
Were Compass Pathways' Clinical Trial Results Really That Bad?
The biotech was priced for perfection; its data wasn't. 
Via The Motley Fool
Exposures Product Safety
10 Biggest Price Target Changes For Monday
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A... 
Via Benzinga
Better Buy: Compass Pathways vs. Jazz Pharmaceuticals
Both of these biotech stocks are innovators, but one is more likely to hit it out of the park. 
Via The Motley Fool
Psychedelic Drug Stocks Continued To Decline Last Week
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
How One Company Says It Aims To Demonstrate the Superiority of Psilocin Over Psilocybin in Treating Mental Health Conditions
Image by Mathew Schwartz from Unsplash The following post was written and/or pu... 
Via Benzinga
Is Now the Right Time to Buy Compass Pathways?
Positive clinical trial results for psilocybin as a depression treatment didn't have the effect on the stock price that shareholders wanted. 
Via The Motley Fool
Why Compass Pathways Stock Slumped This Week
Positive trial results weren't enough to keep the company's shares from sinking this week. 
Via The Motley Fool
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion... 
Via FinancialNewsMedia
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
Compass Pathways reported 
Via Talk Markets
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential
Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why. 
Via InvestorPlace
Is Compass Pathways Stock a Once-in-a-Lifetime Bargain?
Investors might want to give this psychedelic stock another look. 
Via The Motley Fool
75 Biggest Movers From Yesterday
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers... 
Via Benzinga
COMPASS Pathways plc (CMPS) Q3 2021 Earnings Call Transcript
CMPS earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Compass Pathways Shares Are Slumping More Than 22% Tuesday
The stock dropped more than $13 on Tuesday. 
Via The Motley Fool
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial
Shares plunged, despite a psilocybin-based drug reducing depression in a trial. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Frequency Therapeutics (NASDAQ:FREQ) stock rose 10.94% to $7.51 during Tuesday's regular session. The current volume of 277.7K shares is 160.43% of Frequency... 
Via Benzinga
EXCLUSIVE: Benzinga Interviews Mind Cure CEO Kelsey Ramsden with Updates on Latest Press Release
Image by: iStock The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored conte... 
Via Benzinga
Compass Pathways' Psilocybin Therapy Shows Mixed Results From Depression Trial
​​​​​Compass Pathways plc (NASDAQ: CMPS) has announced results from Phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression. The study has... 
Via Benzinga
58 Stocks Moving In Monday's Mid-Day Session
Gainers Dover Motorsports, Inc. (NYSE: DVD) shares climbed 60.3% to $3.59 after Speedway Motorsports announced it will acquire the company for $3.61 per share in cash. TDH... 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.